

Notice Concerning Revision of the Year-end Dividend Forecast for Fiscal Year Ending March 31, 2023 (Dividend Increase)

TOKYO, JAPAN – February 9, 2023 – Terumo Corporation (TSE: 4543) decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows.

1. Details of the Revision

	Dividends per Share		
	End of Second Quarter	End of Fiscal Year	Annual
Previous Forecast	/	19.00 JPY	38.00 JPY
Revised Forecast	/	21.00 JPY	40.00 JPY
FY2022 Actual (Ending March 31, 2023)	19.00 JPY	/	/
FY2021 Actual (Ended March 31, 2022)	16.00 JPY	18.00 JPY	34.00 JPY

(Reference) FY2022 Guidance: Profit attributable to owners of parent = 91.5 billion JPY

2. Reason of the Revision

As a measure to secure high profit margins and sustainable growth, Terumo is committed to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term.

In order to ensure a stable increase in its dividend payouts and to flexibly return profits to shareholders through acquisition of its own shares, Terumo has decided to aim for a total payout ratio* of around 50% during the 5-Year Growth Strategy (GS26). Based on the above reasons, the company decided to increase the forecast for year-end dividends to 21.00 JPY per share. The annual dividends will be 40.00 JPY per share which included the interim dividends on the end of second quarter (19.00 JPY per share).

* The total payout ratio is a financial metric showing the degree of shareholder returns of a company. While the dividend payout ratio indicates the ratio of dividends to net profit, it is calculated by

summing the amount of dividends and acquisition of own shares, and dividing it by net profit.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors.